NEST: Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty (clinicaltrials.gov) - Jul 9, 2026 - P4 | N=50 | Active, not recruiting | Sponsor: HanAll BioPharma Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Endocrine Disorders
|